Evidence map›Paper›PMID 38601470›Full record

ArticleFrontiers in pharmacology2024

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.

Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiroshi Takeda, Hisashi Yokomizo and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Yoshimi MutaDepartment of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.
Kazuo KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Atsuhito ToneDepartment of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital, Okayama, Japan.
Daisuke SuzukiSuzuki Diabetes Clinic, Kanagawa, Japan.
Daisuke TsuriyaDivision of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Hideo MachimuraMachimura Internal Medicine Clinic, Kanagawa, Japan.
Hidetoshi ShimuraShimura Clinic, Kanagawa, Japan.
Hiroshi TakedaTakeda Clinic, Kanagawa, Japan.
Hisashi YokomizoDepartment of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.
Kei TakeshitaDivision of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Keiichi ChinHakuai Clinic, Kanagawa, Japan.
Keizo KanasakiDepartment of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Masaaki MiyauchiMiyauchi Diabetes Clinic, Kanagawa, Japan.
Masuo SaburiDepartment of Diabetology, Endocrinology and Metabolism, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Miwa MoritaDepartment of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.
Miwako YomotaDepartment of Internal Medicine 1, Endocrinology and Metabolism, Shimane University Faculty of Medicine, Shimane, Japan.
Moritsugu KimuraDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Nobuo HatoriKobayashi Hospital, Kanagawa, Japan.
Shinichi NakajimaSagami Junkanki Clinic, Kanagawa, Japan.
Shun ItoDepartment of Internal Medicine, Sagamihara Red Cross Hospital, Kanagawa, Japan.
Shunichiro TsukamotoDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Takashi MurataDepartment of Clinical Nutrition, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Takaya MatsushitaDepartment of Diabetology, Endocrinology and Metabolism, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Takayuki FurukiHadano Station South Gate Clinic, Kanagawa, Japan.
Takuya HashimotoDivision of Endocrinology and Metabolism, 2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Tomoya UmezonoUmezono Internal Medicine Clinic, Kanagawa, Japan.
Yuichi TakashiDepartment of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.
Daiji KawanamiDepartment of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients with type 2 diabetes (T2D). We previously reported that in combination therapy of SGLT2i and GLP1Ra, the effect on the renal composite outcome did not differ according to the preceding drug. However, it remains unclear how the initiation of combination therapy is associated with the renal function depending on the preceding drug. In this

Indexed as

combination therapydiabetic kidney diseaseglucagon-like peptide 1 receptor agonistspreceding drugrenal outcomesodium-glucose cotransporter 2 inhibitors

Identifiers

PMID38601470
PMCPMC11005912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.